红细胞补体受体1单核苷酸多态性与肝细胞癌发病风险的研究

目的 探讨红细胞补体受体1（CR1）单核苷酸多态性（SNP）与肝细胞癌（HCC）发病的关系。方法 收集102例HCC患者（HCC组）和98例健康体检者（对照组）的外周血样本，选取CR1的5个标签SNP位点（rs4844600 G＞A、rs17048010 T＞C、rs3818361 C＞T、rs11118167 T＞C和rs9429945 C＞T）进行检测，分析两组的红细胞CR1基因各SNP位点基因型、等位基因及单体型的分布差异及其与HCC患病风险的关系。同时按照性别、年龄相匹配的原则分别从对照组和HCC组中选取52例和53例样本采用流式细胞术检测其红细胞CR1的几何平均荧光强度比值（GMFIR）。结果 两组rs4844600 G＞A基因型和等位基因分布的差异有统计学意义（P＜0.01）。CR1基因rs4844600 G＞A／GG基因型携带者患HCC的风险为非携带者的2.458倍（95％ CI：1.357～4.451），GA基因型携带者患病风险是非携带者的0.404倍（95％CI：0.218～0.746），其等位基因G携带者患病风险为非携带者的1.945倍（95％CI：1.183～3.199）。rs17048010 T＞C、rs3818361 C＞T、rs11118167 T＞C、rs9429945 C＞T这4个SNP位点和rs11118167-rs3818361-rs17048010／TCT、TTC、CCT、TTT这4种单体型与HCC的患病风险无关（P＞0.05）。HCC组CR1的GMFIR水平为3.257±1.191，高于HCC组的2.652±0.789，差异有统计学意义（t=2.644，P=0.008）。结论 HCC患者红细胞免疫功能降低，CR1基因SNP位点rs4844600 G＞A与HCC发病关联。

Association between single nucleotide polymorphisms of erythrocyte complement receptor type 1 and the susceptibility of hepatocellular carcinoma

Objective To investigate the association between single nucleotide polymorphisms （SNP） of erythrocyte complement receptor type 1（CR1） and the susceptibility of hepatocellular carcinoma （HCC）. Methods This hospital-based case control study was conducted in 102 cases with HCC （HCC group） and 98 healthy controls （Control group）. The plasma samples were collected for the detection of five SNPs （rs4844600 G＞A， rs17048010 T＞C， rs3818361 C＞T， rs11118167 T＞C and rs9429945 C＞T） of erythrocyte CR1. The inter group distributional differences comparison of genotypes， alleles and halotypes of SNPs were examined by the overall odds ratio with a 95％ confidence interval. Meanwhile， according to gender and age matching principle， 52 and 53 samples were chosen from Control group and HCC group for the measurement of geometric mean fluorescence intensity ratio （GMFIR） of CR1. Results There were significant associations between SNP rs4844600 G＞A and the risk for HCC （P＜0.01）. Compared with control group， the risk of developing HCC of carriers of CR1-rs4844600 G＞A／GG genotype increased by 2.458 folds （95％CI： 1.357-4.451） and that of carriers of G allele increased by 1.945 folds （95％CI： 1.183-3.199）， while that of carriers of GA genotype decreased by 0.404 folds （95％CI： 0.218-0.746）. Other four SNPs including rs17048010 T＞C， rs3818361 C＞T， rs11118167 T＞C and rs9429945 C＞T， and haplotypes of rs11118167 rs3818361 rs17048010 containing TCT， TTC， CCT and TTT were not associatied with the risk for HCC （P＞0.05）. The GMFIR of CR1 in HCC group was lower than that in control group （3.257±1.191 vs. 2.652±0.789, P＜0.01）. Conclusion The erythrocyte CR1 level decreases in patients with HCC. SNP rs4844600 G＞A of CR1 gene is associated with HCC.